Vaxart, Inc. Aktie News

Vaxart, Inc. (OTC:VXRT) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Edward Berg - Senior VP & General Counsel Steven Lo - President, CEO & Director James Cummings - Chief Medical Officer Sean Tucker - Senior VP & Chief Scientific Officer Jeroen Grasman - CFO, Principal Accounting Officer & Principal Financial Officer Conference Call Participants Cheng Li - Oppenheim...

Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m.

HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million Board of Directors authorizes new $100 million share repurchase program  Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's n...

Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart to continue leading and funding development through Phase 2b completion and End of Phase 2 meeting with FDA ; Dynavax to receive exclusive, worldwide license and right to assume responsibility for continued ...

SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research highlighting its advances in its norovirus and COVID-19 programs at the World Vaccine Congress E...

In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board's interests with stockholders

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company's previous Phase 2b challenge study -

Question Board's Repeated Delay Tactics and Demand Transparency on Voting Results, Nasdaq Compliance and Governance Changes